Lymph node density as a prognostic indicator for bladder cancer survival: a systematic review and meta-analysis

Precise lymph node staging is critical for prognostic assessment in bladder cancer (BC). Lymph node density (LND), the ratio of positive to total lymph nodes, has emerged as an important prognostic marker that complements conventional TNM staging in various malignancies. We conducted a systematic review and meta-analysis to evaluate the prognostic significance of categorical and continuous LND for overall survival (OS), disease-specific survival (DSS), and disease-free survival (DFS) in BC patients undergoing radical cystectomy (RC). We searched PubMed, Scopus, Embase, and Web of Science from inception until August 11, 2025, for studies examining LND and survival outcomes in BC patients with RC. We pooled hazard ratios (HR) and 95% confidence intervals (CI) using a random-effects model. We included 58 reports with 77,029 patients. Higher LND group was associated with higher hazard of death (HR = 1.97, [95% CI: 1.71–2.26]; I²=31.17%), DSS (HR = 2.24, [95% CI: 1.71–2.92]; I²=88.17%), and DFS (HR = 1.77, [95% CI: 1.48–2.11]; I²=0%). When analyzed as continuous variables, each 1% increment in LND was associated with a 2% higher hazard of death (HR = 1.02, [95% CI: 1.01–1.02]; I²=42.80%), 1% higher hazard of disease-specific death (HR = 1.01, [95% CI: 1.00-1.02]; I²=90.61%), and 2% higher hazard of recurrence (HR = 1.02, [95% CI: 1.01–1.03]; I²=90.31%). Associations remained consistent across cut-off, cohort size, histology, and study-level chemotherapy subgroups. Most included studies were of good quality, and certainty of evidence ranged from moderate to high across outcomes. Publication bias assessment showed no evidence of significant bias. Sensitivity analyses confirmed the robustness of pooled estimates. Limitations include incomplete reporting of lymphadenectomy templates and chemotherapy details. LND is a prognostic indicator for BC patients after RC, enhancing risk stratification. Lymph node density as a prognostic indicator for bladder cancer survival: a systematic review and meta-analysis

Authors

Institutions

Publication Details

Journal
BMC Cancer
Published
2026-10-13
DOI
https://doi.org/10.1186/s12885-026-17146-0
Primary Topic
Bladder and Urothelial Cancer Treatments
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Lymph node density as a prognostic indicator for bladder cancer survival: a systematic review and meta-analysis

Mohammad Reza Nowroozi, Mojtaba Haddad, Erfan Amini, Ali Vaezi et al.
BMC Cancer
Bladder and Urothelial Cancer Treatments
article

Lymph node density as a prognostic indicator for bladder cancer survival: a systematic review and meta-analysis

Mohammad Reza Nowroozi, Mojtaba Haddad, Erfan Amini, Ali Vaezi, Mir Saeed Yekaninejad, Seyed Ali Momeni, Shervin Mossavarali
article en

Abstract

Precise lymph node staging is critical for prognostic assessment in bladder cancer (BC). Lymph node density (LND), the ratio of positive to total lymph nodes, has emerged as an important prognostic marker that complements conventional TNM staging in various malignancies. We conducted a systematic review and meta-analysis to evaluate the prognostic significance of categorical and continuous LND for overall survival (OS), disease-specific survival (DSS), and disease-free survival (DFS) in BC patients undergoing radical cystectomy (RC). We searched PubMed, Scopus, Embase, and Web of Science from inception until August 11, 2025, for studies examining LND and survival outcomes in BC patients with RC. We pooled hazard ratios (HR) and 95% confidence intervals (CI) using a random-effects model. We included 58 reports with 77,029 patients. Higher LND group was associated with higher hazard of death (HR = 1.97, [95% CI: 1.71–2.26]; I²=31.17%), DSS (HR = 2.24, [95% CI: 1.71–2.92]; I²=88.17%), and DFS (HR = 1.77, [95% CI: 1.48–2.11]; I²=0%). When analyzed as continuous variables, each 1% increment in LND was associated with a 2% higher hazard of death (HR = 1.02, [95% CI: 1.01–1.02]; I²=42.80%), 1% higher hazard of disease-specific death (HR = 1.01, [95% CI: 1.00-1.02]; I²=90.61%), and 2% higher hazard of recurrence (HR = 1.02, [95% CI: 1.01–1.03]; I²=90.31%). Associations remained consistent across cut-off, cohort size, histology, and study-level chemotherapy subgroups. Most included studies were of good quality, and certainty of evidence ranged from moderate to high across outcomes. Publication bias assessment showed no evidence of significant bias. Sensitivity analyses confirmed the robustness of pooled estimates. Limitations include incomplete reporting of lymphadenectomy templates and chemotherapy details. LND is a prognostic indicator for BC patients after RC, enhancing risk stratification. Lymph node density as a prognostic indicator for bladder cancer survival: a systematic review and meta-analysis

BMC Cancer
University of Tehran (IR), Uro Oncology Research Center, Tehran University of Medical Sciences (IR)
Openalex Percentile: Top 10%
Bladder and Urothelial Cancer Treatments
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.